|drug668||Calcium Channel Blockers Wiki||1.00|
|drug223||Angiotensin receptor blocker Wiki||1.00|
|drug1490||Hydroxychloroquine Pre-Exposure Prophylaxis Wiki||1.00|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is known to require the angiotensin-converting enzyme 2 (ACE-2) receptor for uptake into the human body, there have been questions about whether medications that upregulate ACE-2 receptors might increase the risk of infection and subsequent complications. One such group of medications are anti-hypertensives that block the renin-angiotensin system, including both angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB). Both ACEi and ARB are widely used for the treatment of hypertension. Early reports from China and Italy suggest that many of those who die from COVID-19 have a coexisting history of hypertension. Consequently, there have been questions raised as to whether these 2 types of blood pressure medication might increase the risk of death among patients with COVID-19. However, it is well known that the prevalence of hypertension increases linearly with age. Therefore, it is possible that the high prevalence of hypertension and ACEi/ARB use among persons who die from COVID-19 is simply confounded by age (older people are at risk of both a history of hypertension and dying from COVID-19). Whether these commonly prescribed blood pressure medications increase the risk of COVID-19 or not remains unanswered. Statements from professional cardiology societies on both sides of the Atlantic have called for urgent research into this question. Our study aims to randomize patients with primary (essential) hypertension who are already taking ACEi/ARB to either switch to an alternative BP medication or continue with the ACEi/ARB that they have already been prescribed. Adults with compelling indications for ACEi/ARB will not be enrolled.
Description: Time from randomization to the first occurrence of any of the clinical events aboveMeasure: Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV) Time: 12 months
Description: Time from randomization to the first occurrence of aboveMeasure: Number of Covid-19 positive participants who die Time: 12 months
Description: Time from randomization to the first occurrence of aboveMeasure: Number of Covid-19 positive participants who require intubation in intensive care unit (ICU) Time: 12 months
Description: Time from randomization to the first occurrence of aboveMeasure: Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV) Time: 12 months
Description: Time from randomization to the first occurrence of aboveMeasure: Number of SARS-CoV-2 positive participants Time: 12 months
Description: Performed in a random sub-sample of the cohort (both study arms)Measure: 24 hour mean systolic BP (mmHg) on ambulatory BP monitoring Time: 12 months
Description: Time from randomization to the first occurrence of aboveMeasure: All-cause mortality Time: 12 months
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports